Frozen versus fresh reconstituted botox for laryngeal dystonia

Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 2, 2006, Pages 204-208

  Thomas, James P ^a   Siupsinskiene, Nora ^b  

^a Private voice center Portland   (United States)

^b KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BREATHING DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPHONIA; DYSTONIA; FEMALE; FREEZING; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INFECTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LARYNX DISORDER; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXIN TYPE A; CROSS-OVER STUDIES; DYSTONIC DISORDERS; FEMALE; FREEZING; HUMANS; LARYNGEAL DISEASES; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS;

EID: 33746480884     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2006.04.001     Document Type: Article

References (12)

1. Blitzer A., Brin M.F., and Stewart C.F. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia). a 12-year experience in more than 900 patients. Laryngoscope 108 (1998) 1435-1441 (Grade C)
2. Rubin A.D., Wodchis W.P., Spak C., et al. Longitudinal effects of Botox injections on Voice-Related Quality of Life (V-RQOL) for patients with adductory spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 130 (2004) 415-420 (Grade C)
3. Anderson Jr. E.R. Proper dose, preparation, and storage of botulinum serotype A. Am J Heath Syst Pharm 22 Suppl (2004) S24-S26 (Grade B)
4. Jabor M.A., Kaushik R., Shayani P., et al. Efficacy of reconstituted and stored botulinum toxin type A. an electrophysiologic and visual study in the auricular muscle of the rabbit. Plast Reconstr Surg 111 (2003) 2419-2426 (Grade B)
5. Sloop R.R., Cole B.A., and Escutin R.O. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 48 (1997) 249-253 (Grade B)
6. Hexel D.M., De Almeida A.T., Rutowitsch M., et al. Multicenter, double-blind study of the efficacy of injections with Botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 29 (2003) 523-529 (Grade A)
7. Bastian R.W. Factors leading to successful evaluation and management of patients with voice disorders. Ear Nose Throat J 67 (1988) 411-420
8. Tisch S.H.D., Brake H.M., Law M., et al. Spasmodic dysphonia. clinical features and effects of botulinum toxin therapy in 169 patients-an Autralian experience. J Clin Neuroscience 10 (2003) 434-438 (Grade C)
9. Sulica L. Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg 12 (2004) 543-548 (Grade B)
10. Gartlan M.G., and Hoffman H.T. Crystalline preparation of botulinum toxin type A (Botox). degradation in potency with storage. Otolaryngol Head Neck Surg 108 (1993) 135 (Grade D)
11. Garcia A., and Fulton J.E. Cosmetic denervation of the muscles of facial expression with botulinum toxin. a dose-response study. Dermatol Surg Oncol 22 (1996) 39-43 (Grade C)
12. Damrose J.F., Goldman S.N., Groessl E., et al. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J of Voice 18 (2004) 415-422 (Grade B)